These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39004413)

  • 21. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.
    Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K
    Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
    Chou D
    Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prelimbic cortex miR-34a contributes to (2R,6R)-hydroxynorketamine-mediated antidepressant-relevant actions.
    Ye L; Xiao X; Xu Y; Zheng C; Chen S; Luo T; Li Z; Du Y; Yuan Y; Li L; Liu B; Qin W; Chou D
    Neuropharmacology; 2022 May; 208():108984. PubMed ID: 35131296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
    Franceschelli A; Sens J; Herchick S; Thelen C; Pitychoutis PM
    Neuroscience; 2015 Apr; 290():49-60. PubMed ID: 25595985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. cAMP-dependent protein kinase signaling is required for (
    Riggs LM; Pereira EFR; Thompson SM; Gould TD
    J Neurophysiol; 2024 Jan; 131(1):64-74. PubMed ID: 38050689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
    Xiong Z; Fujita Y; Zhang K; Pu Y; Chang L; Ma M; Chen J; Hashimoto K
    Behav Brain Res; 2019 Aug; 368():111904. PubMed ID: 30980851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.
    Deyama S; Kondo M; Shimada S; Kaneda K
    Transl Psychiatry; 2022 May; 12(1):178. PubMed ID: 35577782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice.
    Thelen C; Sens J; Mauch J; Pandit R; Pitychoutis PM
    Behav Brain Res; 2016 Oct; 312():305-12. PubMed ID: 27343934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism.
    Ago Y; Tanabe W; Higuchi M; Tsukada S; Tanaka T; Yamaguchi T; Igarashi H; Yokoyama R; Seiriki K; Kasai A; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):665-674. PubMed ID: 31325908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
    Yang C; Kobayashi S; Nakao K; Dong C; Han M; Qu Y; Ren Q; Zhang JC; Ma M; Toki H; Yamaguchi JI; Chaki S; Shirayama Y; Nakazawa K; Manabe T; Hashimoto K
    Biol Psychiatry; 2018 Oct; 84(8):591-600. PubMed ID: 29945718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine.
    Carreno FR; Donegan JJ; Boley AM; Shah A; DeGuzman M; Frazer A; Lodge DJ
    Mol Psychiatry; 2016 Sep; 21(9):1298-308. PubMed ID: 26619811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
    Hashimoto K
    Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
    Aguilar-Valles A; De Gregorio D; Matta-Camacho E; Eslamizade MJ; Khlaifia A; Skaleka A; Lopez-Canul M; Torres-Berrio A; Bermudez S; Rurak GM; Simard S; Salmaso N; Gobbi G; Lacaille JC; Sonenberg N
    Nature; 2021 Feb; 590(7845):315-319. PubMed ID: 33328636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
    Ju L; Yang J; Zhu T; Liu P; Yang J
    BMC Psychiatry; 2022 Mar; 22(1):182. PubMed ID: 35291971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity.
    Riggs LM; Thompson SM; Gould TD
    Neuropharmacology; 2022 Aug; 214():109153. PubMed ID: 35661657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.
    Can A; Zanos P; Moaddel R; Kang HJ; Dossou KS; Wainer IW; Cheer JF; Frost DO; Huang XP; Gould TD
    J Pharmacol Exp Ther; 2016 Oct; 359(1):159-70. PubMed ID: 27469513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of ketamine action as an antidepressant.
    Zanos P; Gould TD
    Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
    Elmer GI; Tapocik JD; Mayo CL; Zanos P; Gould TD
    Pharmacol Biochem Behav; 2020 Sep; 196():172973. PubMed ID: 32569786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
    Farmer CA; Gilbert JR; Moaddel R; George J; Adeojo L; Lovett J; Nugent AC; Kadriu B; Yuan P; Gould TD; Park LT; Zarate CA
    Neuropsychopharmacology; 2020 Jul; 45(8):1398-1404. PubMed ID: 32252062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.